Skip to main
STAA

STAAR Surgical (STAA) Stock Forecast & Price Target

STAAR Surgical (STAA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 13%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Staar Surgical is a key player in the refractive surgery market, and its signature product, the Implantable Collamer Lens (ICL), has shown strong demand in China, the key revenue generator for the company. With a clean Q1 base, solid early demand for the new EVO+ lens, and strong EBITDA numbers, Staar Surgical is on a strong footing and poised for growth in the coming years. However, without full visibility into the numbers and continued caution from management, there may be some potential risks to reaching its full potential.

Bears say

Staar Surgical is positioned for strong growth with a dominant market position in phakic IOLs, continued ex-China growth, and favorable industry dynamics, all of which will contribute to value creation. Despite some one-time costs, the company's improved adjusted EBITDA margin of 12% and management's confirmation of market acceptance of premium pricing for EVO+ suggest a potential for higher profits in the future. However, the company's heavy reliance on foreign sales and slow growth in its main product, ICL, may hinder its overall growth and profitability in the long run.

STAAR Surgical (STAA) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 13% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STAAR Surgical (STAA) Forecast

Analysts have given STAAR Surgical (STAA) a Buy based on their latest research and market trends.

According to 8 analysts, STAAR Surgical (STAA) has a Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STAAR Surgical (STAA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.